Table 2 Characteristics of included studies
Study | Duration of treatment | Study design | Participants | Dose (mg/day) | Previous steroids | Symptom duration (mean) | Sponsorship source | Conflicts of interest |
|---|---|---|---|---|---|---|---|---|
Bousquet 2015 | 1 month | ECR / crossover | Spironolactone Group (n = 8) [n = 7 male and n = 1 female] with mean of age 48 years old and Placebo Group (n = 7) [n = 5 male and n = 2 female] with mean of age 44,7 years old | Spironolacotone group 50 mg / Placebo group 50 mg, once a day (tablets) | Sprinonolactone Group (n = 3) and Placebo Group (n = 2) | Spironolactone Group 12.3 months and Placebo Group (n = 7.4) | Inserm provided financial support for the statistical analysis and was promoter of the study | F. Behar-Cohen and N. Farman are inventors on a patent protecting the use of MR antagonists for retinal edema. The patent rights belong to Inserm. None of the remaining authors have any conflicting interests to disclose |
Pichi 2016 | 1 month (One week + 3 weeks) | ECR / crossover | Spironolactone Group (n = 20); Eplerone Group (n = 20); Placebo Group (n = 20); n = 46 men and 14 women with overall mean age of 51.1 years old | Spironolactone dose (25 mg + 50 mg) / Placebo dose (25 mg + 50 mg) / Eplerone (dose (25 mg + 50 mg), once a day (tablets) | 22 of 60 participants | – | Not informed | No conflicting relationship exists for any author |
Schuwartz 2017 | 6 months (treatment for 3 months) / One week + 11 weeks | ECR / parallel | Eplerone Group (n = 12) [n = 8 male and n = 4 female] with mean of age 50.6 years old / Placebo Group (n = 5) [n = 4 male and n = 1 female] with mean of age 47.2 years old | Eplerone dose (25 mg + 50 mg) and Placebo dose (25 mg + 50 mg), once a day (tablets) | Eplerone Group (n = 3) and Placebo Group (n = 2) | Eplerone Group 3.1 years and Placebo Group 2.2 years | No financial support was given for this study | None declared |
Rahimy 2018 | 9 weeks (one week + 8 weeks | ECR / parallel | Eplerone Group (n = 10) [n = 8 male and n = 2 female] with mean of age 50 years old / Placebo Group (n = 5) [n = 4 male and n = 1 female] with mean of age 62.2 years old | Eplerone dose (25 mg + 50 mg) and Placebo dose (25 mg + 50 mg), once a day (tablets) | – | – | Supported, in part, by an Innovation Grant awarded through Wills Eye Hospital. The funding organization had no role in the design or conduct of the study; management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication | None of the authors has any conflicting interests to disclose |
Lotery 2018 | 12 months (one week + 47 weeks) | ECR / parallel | Eplerone Group (n = 57) [n = 42 male and n = 15 female] with mean of age 47.4 years old / Placebo Group (n = 54) [n = 43 male and n = 14 female] with mean of age 49.9 years old | Eplerone dose (25 mg + 50 mg) and Placebo dose (25 mg + 50 mg), once a day (tablets) | Eplerone Group (n = 12) and Placebo Group (n = 15) | Eplerone Group 8 months (median) and Placebo Group 9 months (median) | This project was funded by the Efficacy and Mechanism Evaluation Programme (13/94/15), which is a Medical Research Council and National Institute for Health Research partnership. The views expressed in this publication are those of the authors and do not necessarily reflect those of the Medical Research Council, National Institute for Health Research, or the Department of Health and Social Care. The funder and the sponsor of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication | AL reports speaker fees from, and has attended advisory board meetings of, Novartis, Bayer, Roche, Allergan, Gyroscope Therapeutics, and Boehringer Ingelheim. SS reports research grants and speaker fees from, and has attended advisory board meetings of, Novartis, Bayer, Roche, Allergan, Optos, Heidelberg Engineering, and Boehringer Ingelheim. FB-C is an inventor on a patent protecting the use of mineralocorticoid receptor antagonists for retinal oedema. TP reports research grants and speaker fees from, and has attended advisory board meetings of, Novartis, Bayer, Roche, Optos, Heidelberg Engineering, Welch Allyn, and Boehringer Ingelheim. All other authors declare no competing interests |